Physicians news and physicians widget

To conserve cash, General Motors will cut lifetime health care for management retirees at the end of this year.

MyVetwork, a service launched today in honor of Veterans Day, is a non-profit social Web community that seeks to bring together ...

Researchers at the University of Pennsylvania School of medicine and colleagues in the United Kingdom have engineered T cells able to recognize HIV-1 strains that have evaded the immune system.

Feminist Alix Kates Shulman's newest book, To Love What Is: A Marriage Transformed is a memoir of her life with sculptor Scott ...

Using Crestor to prevent heart attacks and save lives in apparently healthy people would add nearly $10 billion a year to the ...

Sartorius Stedim Biotech (SSB), a group subsidiary of the biotechnology supplier, Sartorius Stedim Biotech, signed an agreement to acquire the Swiss-based technology company, Wave Biotech. Both companies have already been closely working together since 2006. In addition to their joint research projects, Sartorius Stedim Biotech has been exclusively marketing Wave's entire product range, which covers various types of single-use bioreactors and further equipment for biopharmaceutical research and manufacture. During the current financial year, SSB's sales revenue with Wave products is expected ...

Medical experts from UK charities concerned about the rise in miracle cure stories, wonder drugs and so-called breakthrough therapies have teamed up to produce a guide that explains how to tell the beneficial from the bogus.

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced top-line data from its SB-509-601 clinical trial, one of Sangamo's three Phase 2 clinical studies from its ZFP Therapeutic(TM) program to develop SB-509 for diabetic neuropathy (DN). The data demonstrate that repeat administration of the drug is well tolerated in subjects with mild to moderate DN.

Rheumatoid arthritis is a painful, inflammatory type of arthritis that occurs when the body's immune system attacks itself. A new paper, published in this week's issue of PLoS Biology, reports a breakthrough in the understanding of how autoimmune responses can be controlled, offering a promising new strategy for therapy development for rheumatoid arthritis.

MONTEREY, CA, USA (UroToday.com) - Dr. Saad Juma presented his experience in 234 patients who had completed a 12 to 26 month (mean 23.3) questionnaire follow up after placement of an ArisT transobuturator sling. The group reported resolution of SUI in 90.61% of the patients, of urge incontinence in 61.81%, and only 2.51% (n=2) with de novo urgency symptoms.